Skip to main content
Premium Trial:

Request an Annual Quote

Morphosys Extends Research Agreement with Pharma Firm Shionogi

Premium

Morphosys said it has agreed to a three-year extension of its ongoing research partnership with Japanese pharma firm Shionogi.

The agreement covers Shionogi's use of Morphosys' HuCal antibody platform for drug development research in exchange for annual user fees. Further financial details were not disclosed.

The project will be run on Morphosys' end by its AbD Serotec unit. Shionogi will have the right to use the company's HuCAL Platinum antibody library for research purposes at one of its research sites.

AbD Serotec uses its HuCAL – or Human Combinatorial Antibody Library – platform to generate monoclonal antibodies for research and diagnostic applications. The platform consists of a collection of several billion distinct fully human antibodies that, according to the company's website, allows for the rapid selection of antibodies with high affinity and specificity.

Morphosys and Shionogi first signed a license agreement for the use of the HuCAL platform in September 2005.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.